FDA approves additional formulation of biosimilar
US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.
Search
FDA Approves sNDA for BI’s Stiolto® Respimat® | BI US
FDA approves an sNDA for STIOLTO® RESPIMAT® (tiotropium bromide & olodaterol) showing improvement in quality of life in COPD patients. View ISI, PI & Med Guide.
About our Innovation Prize
Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.
Our Innovation Prize | Partnering
Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.
Helping pets after a natural disaster in the Carolinas
Helping pets after a natural disaster in the Carolinas
U.S. FDA grants Breakthrough Therapy designation for MASH
Boehringer Ingelheim receives U.S. FDA Breakthrough Therapy designation for people living with MASH and liver fibrosis
Worldwide Partnering Contacts
Worldwide Partnering Contacts
Human Health Partnering
Human Health Partnering
Interview with Norbert Kraut: How cancer drives us forward
Norbert Kraut, our Global Head of Cancer Research at Boehringer Ingelheim, shares our approach to advancing cancer research and exploring new technologies
From garage start-up to global pharma: combining strengths to advance regenerative medicine
Article describing how a strategic partnership between Global Stem Cell and Boehringer Ingelheim Animal Health has played a key role in helping the companies accelerate breakthroughs in regenerative medicine.
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Our Respiratory Partnering Interests
Our Respiratory Partnering Interests
Our Immunology Partnering Interests
Our Immunology Partnering Interests
Partnering Interests in CardioMetabolic Diseases
Partnering Interests in CardioMetabolic Diseases
Our Technology Partnering Interests
Our Technology Partnering Interests
Your Guide to Partnering with Us
Your Guide to Partnering with Us
Focus on Alliance Management
Focus on Alliance Management
Meet our scientist
Colleagues explain why they chose Boehringer Ingelheim
Our Retinal Health Partnering Interests
Our Retinal Health Partnering Interests
Our Biotherapeutic Technology Partnering Interests
Our Biotherapeutic Technology Partnering Interests
Corporate Profile
Corporate Profile
Digital solutions save lives
Digital solutions save lives
Our Research Beyond Borders Partnering Interests
Our Research Beyond Borders Partnering Interests
Our Central Nervous System Partnering Interests
Our Central Nervous System Partnering Interests
Protecting Humans & Animals | COVID-19 | Boehringer Ingelheim US
Read more on Boehringer Ingelheim's commitment to protecting both humans and animals during the COVID-19 pandemic.